Search research articles
Contact Us
Filters
Showing results (121-130 of 383) with videos related to
Page
of 39
Sort By:
British Journal of Haematology
|
July 24, 2015
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
Peter M Voorhees, Robert Z Orlowski, Flora Mulkey, et al.
Leukemia Research
|
April 9, 2019
Patients' perspectives on the definition of cure in chronic myeloid leukemia
Kathryn E Flynn, Michael J Mauro, Gemlyn George, et al.
Cytotherapy
|
May 3, 2012
Influence of related donor age on outcomes after peripheral blood stem cell transplantation
Elie M Richa, Rangesh Kunnavakkam, Lucy A Godley, et al.
British Journal of Clinical Pharmacology
|
May 20, 2014
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
Xiaofeng Wang, Kouros Owzar, Pankaj Gupta, et al.
Leukemia & Lymphoma
|
December 25, 2015
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment
Christopher R D'Angelo, Masha Kocherginsky, Jennifer Pisano, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 23, 2008
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation
Andrew S Artz, Amittha Wickrema, Shira Dinner, et al.
Blood
|
May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.
Leukemia Research
|
August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
Richard M Stone, Barry Moser, Ben Sanford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study
John F DiPersio, Harry P Erba, Richard A Larson, et al.
Page
of 39
Search research articles
Search
Showing results (121-130 of 383) with videos related to
Sort By:
Page
of 39
British Journal of Haematology
|
July 24, 2015
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
Peter M Voorhees, Robert Z Orlowski, Flora Mulkey, et al.
Leukemia Research
|
April 9, 2019
Patients' perspectives on the definition of cure in chronic myeloid leukemia
Kathryn E Flynn, Michael J Mauro, Gemlyn George, et al.
Cytotherapy
|
May 3, 2012
Influence of related donor age on outcomes after peripheral blood stem cell transplantation
Elie M Richa, Rangesh Kunnavakkam, Lucy A Godley, et al.
British Journal of Clinical Pharmacology
|
May 20, 2014
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
Xiaofeng Wang, Kouros Owzar, Pankaj Gupta, et al.
Leukemia & Lymphoma
|
December 25, 2015
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment
Christopher R D'Angelo, Masha Kocherginsky, Jennifer Pisano, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 23, 2008
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation
Andrew S Artz, Amittha Wickrema, Shira Dinner, et al.
Blood
|
May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.
Leukemia Research
|
August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
Richard M Stone, Barry Moser, Ben Sanford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study
John F DiPersio, Harry P Erba, Richard A Larson, et al.
Page
of 39